← Back

Tenon Medical Inc

Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive inferior-posterior approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.

Price · split & dividend adjusted
News & notes moving TNON
Biotech & Genomic Medicine▲

Tenon Medical outlines sacropelvic launches after FDA clearance

Tenon Medical reported second quarter revenue of $1.3 million, up 127% year over year, and gross profit of $0.8 million, up 232%, while outlining a cadence of sacropelvic product launches over the next six to nine months. The company received FDA 510(k) clearance for its Catamaran SI Joint Fusion System on July 2, with updated instruments expected to improve margins beginning in Q3. Tenon also closed a public offering on July 1 for gross proceeds of $4.2 million, adding to its $1.7 million cash position at quarter end. Management did not provide formal guidance but said an enhanced SImmetry+ system will become clinically active in Q3 and a novel posterior technology is being prepared for FDA submission.
TNON ▲
Biotech & Genomic Medicine ▲
Seeking Alpha·13dRead more ▾
TNON

Tenon Medical Implements 1-for-35 Reverse Stock Split Today

Tenon Medical announced it will implement a 1-for-35 reverse stock split effective at 12:01 Eastern Time on August 10, 2026. The move is intended to raise the per-share trading price to meet Nasdaq's minimum $1.00 average closing price requirement for continued listing on the Nasdaq Capital Market. Shares will begin trading on a split-adjusted basis under the ticker symbol TNON with a new CUSIP number, and no fractional shares will be issued, with positions rounded up to the nearest whole share. The reverse split does not alter the company's fundamentals but is a mechanical adjustment to maintain compliance with Nasdaq listing requirements. Tenon Medical, based in Los Gatos, California, develops sacroiliac joint fusion systems including the Catamaran SI Joint Fusion System and SImmetry+ SI Joint Fusion System.
TNON
RTTNews·17dRead more ▾
Biotech & Genomic Medicine▲

Tenon, Nuvectis, REGENXBIO Lead Biotech Gainers on Filings and Deals

Several biotech stocks posted sharp gains Monday, led by Tenon Medical after an S-1 filing, Nuvectis Pharma on a licensing deal with Haisco, and REGENXBIO on a regulatory reversal for its Hunter syndrome gene therapy. Tenon filed to offer up to 1.81 million shares and 6.98 million warrants at $0.6021 per unit, with shares closing up 77.57% at $0.62. Nuvectis announced exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, from Haisco Pharmaceutical Group, sending its stock up 19.61% to $16.53. REGENXBIO gained 16.28% to $9.07 after the FDA agreed that existing data for NAVSUNLI is sufficient for an accelerated approval resubmission, with a Type A meeting set for next month and BLA resubmission expected in the third quarter of 2026. Other notable movers included Azitra, up 33.95% after a shareholder letter outlined a 2026 roadmap for its cosmetic ingredient program ATR-COSF, and Apollomics and Faeth Therapeutics, both rising over 30% on no specific news.
NVCT ▲RGNX ▲TNON ▲AZTR ▲
Biotech & Genomic Medicine ▲
RTTNews·65dRead more ▾
© 2026 MarketDXAsset